Table 6.
Klebsiella pneumoniae isolates from bloodstream infections’ resistance profiles.
| Agent | MIC50 | MIC90 | Range | Count | CLSI a | EUCAST a | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %S | %I | %R | Count | %S | %I | %R | Count | |||||
| Amikacin | 1 | 8 | ≤0.25 to >32 | 6897 | 93.5 | 3.0 | 3.5 | 6897 | 91.3 | 8.7 b | 6897 | |
| Gentamicin | ≤1 | >8 | ≤1 to >8 | 6899 | 81.6 | 0.9 | 17.5 | 6899 | 81.0 | 19.0 b | 6899 | |
| Tobramycin | 0.5 | >8 | ≤0.12 to >8 | 6897 | 74.1 | 4.8 | 21.1 | 6897 | 72.5 | 27.5 b | 6897 | |
| Amoxicillin-clavulanic acid | 4 | >8 | ≤1 to >8 | 4662 | 67.6 | 8.6 | 12.1 | 4662 | ||||
| Ampicillin-sulbactam | 8 | >32 | ≤0.5 to >32 | 6901 | 56.4 | 7.0 | 36.7 | 6901 | 56.4 | 43.6 c | 6901 | |
| Cefoperazone-sulbactam | ≤0.25 | >32 | ≤0.25 to >32 | 5723 | 78.1 | 21.9 d | 5723 | |||||
| Ceftazidime-avibactam | 0.12 | 1 | ≤0.015 to >32 | 1074 | 98.5 | 1.5 | 1074 | 98.5 | 1.5 | 1074 | ||
| Ceftolozane-tazobactam | 0.25 | >16 | ≤0.12 to >16 | 1073 | 84.5 | 1.4 | 14.1 | 1073 | 84.5 | 15.5 | 1073 | |
| Piperacillin-tazobactam | 4 | >64 | ≤0.5 to >64 | 6891 | 78.1 | 5.1 | 16.8 | 6891 | 71.9 | 28.1 | 6891 | |
| Doripenem | ≤0.12 | 2 | ≤0.12 to >4 | 5827 | 89.5 | 0.8 | 9.7 | 5827 | 89.5 | 0.8 | 9.7 | 5827 |
| Ertapenem | 0.015 | >2 | ≤0.008 to >2 | 2888 | 85.2 | 1.0 | 13.8 | 2888 | 85.2 | 14.8 | 2888 | |
| Imipenem | ≤0.12 | 2 | ≤0.12 to >8 | 6899 | 89.4 | 1.0 | 9.6 | 6899 | 90.4 | 1.2 | 8.4 | 6899 |
| Meropenem | ≤0.06 | 2 | ≤0.06 to >8 | 6899 | 89.4 | 0.8 | 9.8 | 6899 | 90.2 | 9.8 e | 6899 | |
| 90.2 | 1.7 | 8.0 f | 6899 | |||||||||
| Cefepime | ≤0.5 | >16 | ≤0.5 to >16 | 6899 | 70.9 | 2.5 | 26.6 g | 6899 | 69.9 | 2.0 | 28.1 | 6899 |
| Cefoperazone | 0.5 | >32 | ≤0.25 to >32 | 1450 | 68.1 | 0.9 | 31.0 d | 1450 | ||||
| Cefoxitin | 4 | >16 | 1 to >16 | 883 | 77.5 | 4.6 | 17.9 | 883 | ||||
| Ceftaroline | 0.12 | >16 | ≤0.03 to >16 | 6738 | 65.0 | 2.0 | 33.0 | 6738 | 65.0 | 35.0 | 6738 | |
| Ceftazidime | 0.25 | >16 | ≤0.12 to >16 | 6901 | 70.3 | 2.3 | 27.4 | 6901 | 68.4 | 1.9 | 29.7 | 6901 |
| Ceftriaxone | ≤0.06 | >8 | ≤0.06 to >8 | 6899 | 68.8 | 0.6 | 30.6 | 6899 | 68.8 | 31.2 e | 6899 | |
| 68.8 | 0.6 | 30.6 f | 6899 | |||||||||
| Cefuroxime | 4 | >64 | ≤0.5 to >64 | 2458 | 53.5 | 8.5 | 37.9 h | 2458 | 58.8 | 41.2 j | 2458 | |
| 58.8 | 3.3 | 37.9 i | 2458 | |||||||||
| Trimethoprim-sulfamethoxazole | ≤0.5 | >4 | ≤0.5 to >4 | 6893 | 67.0 | 33.0 | 6893 | 67.0 | 1.1 | 31.9 | 6893 | |
| Tigecycline | 0.5 | 1 | ≤0.06 to 8 | 6893 | 98.0 | 1.7 | 0.2 k | 6893 | ||||
| Colistin | ≤0.5 | ≤0.5 | ≤0.5 to >8 | 6848 | 95.8 | 4.2 | 6848 | |||||
| Polymyxin B | 1 | 1 | ≤0.25 to >8 | 1757 | ||||||||
| Aztreonam | ≤0.12 | >16 | ≤0.12 to >16 | 6899 | 70.5 | 0.8 | 28.7 | 6899 | 69.2 | 1.3 | 29.5 | 6899 |
| Ciprofloxacin | ≤0.03 | >4 | ≤0.03 to >4 | 6884 | 65.2 | 4.1 | 30.7 | 6884 | 65.2 | 4.1 | 30.7 | 6884 |
| Levofloxacin | ≤0.12 | >4 | ≤0.12 to >4 | 6884 | 70.9 | 5.0 | 24.1 | 6884 | 70.9 | 5.0 | 24.1 | 6884 |
| Moxifloxacin | ≤0.25 | >4 | ≤0.25 to >4 | 5465 | 60.3 | 39.7 | 5465 | |||||
| Doxycycline | 2 | >8 | 0.12 to >8 | 6372 | 69.5 | 6.6 | 23.9 | 6372 | ||||
| Minocycline | 2 | >8 | ≤0.06 to >8 | 6521 | 78.8 | 7.7 | 13.4 | 6521 | ||||
| Tetracycline | 2 | >8 | ≤0.5 to >8 | 6526 | 68.6 | 3.8 | 27.6 | 6526 | ||||
a Criteria as published by CLSI (2021) and EUCAST (2021). b For infections originating from the urinary tract. For systemic infections, aminoglycosides must be used in combination with other active therapy. c These breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. d The cefoperazone breakpoints were applied following US FDA criteria. e Using meningitis breakpoints. f Using non-meningitis breakpoints. g Intermediate is interpreted as susceptible-dose dependent. h Using oral breakpoints. i Using parenteral breakpoints. j Using oral, uncomplicated urinary tract infection only breakpoints. k US FDA breakpoints were applied. Organisms included: Klebsiella pneumoniae (6901). Report generated using MVP (https://sentry-mvp.jmilabs.com, assessed on 4 June 2021), a product of JMI Laboratories, on 5 June 2021 11:09:47 GMT/UTC. The data and information are available in the SENTRY Antimicrobial Surveillance Program dataset.